CLSD CLEARSIDE BIOMEDICAL INC Investments/Divestments 8-K Filing 2023 - License Agreement with BioCryst Pharmaceuticals Clearside Biomedical, Inc. entered into a license agreement with BioCryst Pharmaceuticals, granting BioCryst an exclusive license for the delivery of avoralstat for the treatment of diabetic macular edema, with potential milestone payments and royalties.Get access to all SEC 8-K filings of the CLEARSIDE BIOMEDICAL INC